Fucidin® Cream in the Treatment of Impetigo

• Status: Terminated
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients.

To assess the validity of in vitro susceptibility-testing of S. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with Fucidin® cream.

To investigate the genetic relationship between S. aureus-strains isolated from impetigo patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma
• Treatments: Fusidic Acid

Criteria

Inclusion Criteria:

• Patients with a clinical diagnosis of impetigo,

• Patients aged 2-11 years,

• Patients of either sex,

• Patients whose parent(s) has(ve) provided written consent, AND

• Patients with a severity score of 1 for at least one of the following signs:

pustules/infected bullae, erythema and infiltration/induration.

Exclusion Criteria:

• Patients with other active inflammatory dermatitis at the area of impetigo,

• Patients with a temperature above 38.5 C rectally (or equivalent), OR

• Patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.